Questions of ethical regulation of immunobiological therapy of some occupational lung diseases

Objective. Taking into account a high prevalence of occupational pathology associated with the exposure industrial aerosols, to analyze principles therapy used for patients these diseases.
 Materials and methods. The regulating medical documents, data preventive examinations as well applied diseases, which are presented in scientific literarure, analyzed.
 Results. role harmful production factors formation pneumoconiosis alveolitis, join group interstitial lung diseases (ILD), has been proved. outcome is fibrosing alveolitis development diffuse pulmonary fibrosis. In treatment ILD, immunobiological drugs (IBD) suppress immune processes selectively affecting monoclonal antibodies, blocking interrupts inflammation 90 % cases stops further disease.
 Conclusions. use clinical practice should be carried out within framework ethical legal regulation between patient doctor.